BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. RESULTS: A total of 32 patients (43%) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response. CONCLUSIONS: Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.
BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. RESULTS: A total of 32 patients (43%) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response. CONCLUSIONS: Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.
Authors: Bouke P C Hazenberg; Alexandra Croockewit; Bronno van der Holt; Sonja Zweegman; Gerard M J Bos; Michel Delforge; Reinier A P Raymakers; Pieter Sonneveld; Edo Vellenga; Pierre W Wijermans; Peter A von dem Borne; Marinus H van Oers; Okke de Weerdt; Fokje M Spoelstra; Henk M Lokhorst Journal: Haematologica Date: 2015-02-06 Impact factor: 9.941
Authors: N Tandon; E Muchtar; S Sidana; A Dispenzieri; M Q Lacy; D Dingli; F K Buadi; S R Hayman; R Chakraborty; W J Hogan; W Gonsalves; R Warsame; T V Kourelis; N Leung; P Kapoor; S K Kumar; M A Gertz Journal: Bone Marrow Transplant Date: 2017-04-10 Impact factor: 5.483
Authors: Christopher P Venner; Julian D Gillmore; Sajitha Sachchithanantham; Shameem Mahmood; Thirusha Lane; Darren Foard; Murielle Roussel; Lisa Rannigan; Simon Dj Gibbs; Jennifer H Pinney; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Ashutosh D Wechalekar Journal: Haematologica Date: 2014-09-05 Impact factor: 9.941
Authors: C P Venner; J D Gillmore; S Sachchithanantham; S Mahmood; T Lane; D Foard; L Rannigan; S D J Gibbs; J H Pinney; C J Whelan; H J Lachmann; P N Hawkins; A D Wechalekar Journal: Leukemia Date: 2014-07-16 Impact factor: 11.528
Authors: Eli Muchtar; Angela Dispenzieri; Shaji K Kumar; David Dingli; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Rajshekhar Chakraborty; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz Journal: Haematologica Date: 2016-06-16 Impact factor: 9.941
Authors: Taxiarchis V Kourelis; Shaji K Kumar; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Steven Zeldenrust; Nelson Leung; Robert A Kyle; Stephen Russell; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; S Vincent Rajkumar; Arleigh McCurdy; Angela Dispenzieri Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544